Sagent Pharmaceuticals Announces Launch of Oxacillin for Injection, USP
SCHAUMBURG, Ill., July 24, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Oxacillin for Injection, USP, in three latex-free, preservative-free vial presentations. According to IMS data for the twelve-months ended May 2012, the U.S. market for Oxacillin approximated $29 million. As with all products in Sagent's portfolio, Oxacillin features the company's PreventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors.
About Oxacillin for Injection, USP
Oxacillin for Injection, USP is a semisynthetic penicillin indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug.
The package insert, which is available at www.SagentPharma.com, contains detailed information about the indications, complete side effect profile, and prescribing information.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive pharmaceutical product portfolio that fulfills the evolving needs of patients.
CONTACT: INVESTOR CONTACT:
Jonathon Singer, Sagent
Source: Sagent Pharmaceuticals, Inc.
News Provided by Acquire Media
Close window | Back to top